Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

NCT04595370 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure
Chronic Kidney Disease

Interventions

DRUG: AZD9977
DRUG: Dapagliflozin

Sponsor

AstraZeneca